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Abstract 
Excessive alcohol consumption is a major public health problem worldwide. While 
drinking habits are known to be inherited, few genes have been identified that are 
robustly linked to alcohol drinking. We conducted a genome-wide association meta-
analysis and replication study among >105,000 individuals of European ancestry, and 
identified β-Klotho (KLB) as a locus associated with alcohol consumption (rs11940694; 
P=9.2x10-12). β-Klotho is an obligate co-receptor for the hormone FGF21, which is 
secreted from the liver and implicated in macronutrient preference in man. We show 
that brain-specific β-Klotho knock-out mice have an increased alcohol preference and 
that FGF21 inhibits alcohol drinking by acting on the brain. These data suggest that a 
liver-brain endocrine axis may play an important role in the regulation of alcohol drinking 
behavior and provide a unique pharmacologic target for reducing alcohol consumption. 
 
Keywords:  alcohol consumption, human, mouse model, brain, β-Klotho, FGF21 
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Significance 
Alcohol is a widely consumed drug in western societies that can lead to addiction. A 
small shift in consumption can have dramatic consequences on public health. We 
performed the largest genome-wide association meta-analysis and replication study to 
date (>105,000 individuals) and identified a new genetic basis for alcohol consumption 
during non-addictive drinking. We found a locus in the gene encoding β-Klotho (KLB) is 
associated with alcohol consumption. β-Klotho is an essential receptor component for 
the endocrine fibroblast growth factors (FGFs) 19 and 21. Using mouse models and 
pharmacologic administration of FGF21, we demonstrate that β-Klotho in the brain 
controls alcohol drinking. These findings reveal a mechanism regulating alcohol 
consumption in humans that may be pharmacologically tractable for reducing alcohol 
intake.  
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Introduction 
Excessive alcohol consumption is a major public health problem worldwide causing an 
estimated 3.3 million deaths in 2012 (1). Much of the behavioral research associated 
with alcohol has focused on alcohol-dependent patients. However, the burden of 
alcohol-associated disease largely reflects the amount of alcohol consumption in a 
population, not alcohol dependence (2). It has long been recognized that small shifts in 
the mean of a continuously distributed behavior such as alcohol drinking can have 
major public health benefits (3). For example, a shift from heavy to moderate drinking 
could have beneficial effects on cardiovascular disease risk (4). 
 
Alcohol drinking is a heritable complex trait (5). Genetic variants in the alcohol and 
aldehyde dehydrogenase gene family can result in alcohol intolerance caused by 
altering peripheral alcohol metabolism, and may thus influence alcohol consumption 
and dependence (6). However, genetic influences on brain functions affecting drinking 
behavior have been more difficult to detect because, as for many complex traits, the 
effect of individual genes is small, so large sample sizes are required to detect the 
genetic signal (7). 
 
Here we report a genome-wide association (GWAS) and replication study of over 
100,000 individuals of European descent. We identify a gene variant in β-Klotho (KLB) 
that associates with alcohol consumption. β-Klotho is a single-pass transmembrane 
protein that complexes with FGF receptors to form cell surface receptors for the 
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hormones FGF19 and FGF21 (8, 9). FGF19 is induced by bile acids in the small 
intestine to regulate bile acid homeostasis and metabolism in the liver (9). FGF21 is 
induced in liver and released into the blood in response to various metabolic stresses, 
including high carbohydrate diets and alcohol (10-12). Notably, FGF21 was recently 
associated in a human GWAS study with macronutrient preference, including changes 
in carbohydrate, protein and fat intake (13). Moreover, FGF21 was shown to suppress 
sweet and alcohol preference in mice (14, 15). Our current findings suggest that the 
FGF21-β-Klotho signaling pathway regulates alcohol consumption in humans. 
 
Results 
Association of KLB gene SNP rs11940694 with alcohol drinking in humans 
We carried out a GWAS of quantitative data on alcohol intake in 70,460 individuals 
(60.9% women) of European descent from 30 cohorts. We followed up the most 
significantly associated SNPs (six sentinel SNPs P<1.0x10-6 from independent regions) 
among up to 35,438 individuals from 14 additional cohorts (Dataset S1; and Appendix 
1). We analyzed both continuous data on daily alcohol intake in drinkers (as g/day, log 
transformed) and a dichotomous variable of heavy versus light or no drinking (Dataset 
S1). Average alcohol intake in drinkers across the samples was 14.0 g/day in men and 
6.0 g/day in women. We performed per cohort sex-specific and combined-sex single 
SNP regression analyses under an additive genetic model, and conducted meta-
analysis across the sex-specific strata and cohorts using an inverse variance weighted 
fixed effects model.  
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Results of the primary GWAS for log g/day alcohol are shown in Figures 1 and S1, 
Dataset S2. We identified five SNPs for replication at P<1x10-6: rs11940694 in the KLB 
gene, rs197273 in TANK, rs780094 in GCKR, rs350721 in ASB3 and rs10950202 in 
AUTS2 (Table 1, Dataset S2). In addition to rs10950202 in AUTS2 (P=2.9x10-7), we 
took forward SNP rs6943555 in AUTS2 (P=1.4x10-4), which was previously reported in 
relation to alcohol drinking (7). In both men and women the newly discovered SNPs 
were all significantly associated with log g/day alcohol at P<0.005 (Table S1). When 
combining discovery and replication data, we observed genome-wide significance for 
SNP rs11940694 (A/G) in KLB (P=9.2x10-12) (Table 1 and Figure S1), for which the 
minor allele A was associated with reduced drinking. KLB is localized on human 
chromosome 4p14 and encodes a transmembrane protein, β-Klotho, which is an 
essential component of receptors for FGF19 and FGF21 (8, 9). Rs197273 in the TRAF 
family member-associated NF-kappa-B activator gene (TANK) narrowly missed 
reaching genome-wide significance in the combined sample (Table 1; P=7.4x10-8). In 
the dichotomous analysis of the primary GWAS, SNP rs12599112 in the Cadherin 13 
gene (CDH13) and rs10927848 in the Transmembrane protein 82 gene (TMEM82) were 
significant at P=2.3x10-8 and P=2.6x10-7, respectively (Figure S2, Table S2 and Dataset 
S2), but did not reach genome wide significance in the combined analysis (Table S2). 
 
SNP rs11940694 is localized in intron 1 of the KLB gene. The local linkage 
disequilibrium (LD) structure of the KLB gene is shown in Figure S3. The minor allele 
frequencies of this SNP were generally high (between 0.37 and 0.44) in different ethnic 
groups (Table S3). We found no significant association of rs11940694 with gene 
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expression in peripheral blood of 5,236 participants of the Framingham study (Table S4) 
(16). 
 
β-Klotho in the brain controls alcohol drinking in mice 
To examine whether β-Klotho affects alcohol drinking in mice, and whether it does so 
through actions in the brain, we measured alcohol intake and the alcohol preference ratio 
of brain-specific β-Klotho-knockout (KlbCamk2a) mice and control floxed Klb (Klbfl/fl) mice. 
We used a voluntary two-bottle drinking assay performed with water and alcohol. Since we 
previously showed that FGF21-transgenic mice, which express FGF21 at pharmacologic 
levels, have a reduced alcohol preference (14), we performed these studies while 
administering either recombinant FGF21 or vehicle by osmotic minipump. Alcohol 
preference versus water was significantly increased in vehicle-treated KlbCamk2a 
compared to Klbfl/fl mice at 16 vol. % alcohol (Fig. 2A). FGF21 suppressed alcohol 
preference in Klbfl/fl mice, but not in KlbCamk2a demonstrating that the effect of FGF21 on 
alcohol drinking depends on β-Klotho expressed in the brain (Fig. 2A). There was a 
corresponding decrease in plasma alcohol levels immediately after 16 vol. % alcohol 
drinking, which reflects the modulation of the drinking behavior (Fig. 2B). However, 
plasma FGF21 levels were comparable in Klbfl/fl and KlbCamk2a mice administered 
recombinant FGF21 at the end of the experiment (Fig. 2C). Alcohol bioavailability was 
not different between FGF21 treated Klbfl/fl and KlbCamk2a mice (Fig. 2D). We have 
previously shown that FGF21 decreases the sucrose and saccharin preference ratio in 
Klbfl/fl but not KlbCamk2a mice, and has no effect on the quinine preference ratio (14). To 
rule out a potential perturbation of our findings as a result of the experimental 
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procedure, we independently measured preference and consumption of 16 vol. % 
alcohol in Klbfl/fl and KlbCamk2a mice without osmotic minipump implantation. Again, 
KlbCamk2a mice showed significantly greater alcohol consumption and increased alcohol 
preference compared to Klbfl/fl mice (Fig. 2E and F), thus replicating our findings above. 
Alcohol bioavailability after an intraperitoneal injection was not different between Klbfl/fl and 
KlbCamk2a mice after 1 and 3 hours (Fig. 2G).  
 
β-Klotho in brain does not regulate emotional behavior in mice 
Increased alcohol drinking in humans and mice may be motivated by its reward 
properties or as a means to relieve anxiety and stress (17). In mice, FGF21 increases 
corticotropin-releasing hormone expression in hypothalamus, circulating glucocorticoid 
concentrations and sympathetic outflow (18-20), which are linked to heightened anxiety. 
We therefore tested Klbfl/fl and KlbCamk2a mice in behavioral paradigms measuring anxiety, 
including novelty suppressed feeding (Fig. 3A), elevated plus maze (Fig. 3B), and open 
field activity tests (Fig. 3C). However, we did not find differences between Klbfl/fl and 
KlbCamk2a mice in any of these anxiety measures or in general locomotor activity. Our 
finding of increased alcohol preference in KlbCamk2a mice may thus be caused by alteration 
of alcohol-associated reward mechanisms. While this notion is consistent with our 
previous results showing Klb expression in areas important for alcohol reinforcement, 
specifically the nucleus accumbens and the ventral tegmental area (14), additional studies 
will be required to determine precisely where in the brain and how β-Klotho affects alcohol 
drinking. 
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Discussion 
Here we report that in a GWAS performed in over 100,000 individuals, SNP rs11940694 
in KLB associates with alcohol consumption in non-addicts. We further show that mice 
lacking β-Klotho in the brain have increased alcohol consumption and are refractory to 
the inhibitory effect of FGF21 on alcohol consumption. These findings reveal a 
previously unrecognized brain pathway regulating alcohol consumption in humans that 
may prove pharmacologically tractable for suppressing alcohol drinking.  
 
FGF21 is induced in liver by simple sugars through a mechanism involving the 
transcription factor carbohydrate response element binding protein (10, 11, 15, 21, 22). 
FGF21 in turn acts on brain to suppress sweet preference (14, 15). Thus, FGF21 is part 
of a liver-brain feedback loop that limits the consumption of simple sugars. Notably, 
FGF21 is also strongly induced in liver by alcohol and contributes to alcohol-induced 
adipose tissue lipolysis in a mouse model of chronic-binge alcohol consumption (12). 
Our present data suggest the existence of an analogous feedback loop wherein liver-
derived FGF21 acts on brain to limit the consumption of alcohol. However, additional 
studies will be required to establish the existence of this FGF21 pathway in vivo. 
 
In murine brain, there is evidence that FGF21 suppresses sweet preference through 
effects on the paraventricular nucleus in the hypothalamus (15). Among its actions in the 
hypothalamus, FGF21 induces corticotropin-releasing hormone (18, 19), which is a 
strong modulator of alcohol consumption (23). Notably, β-Klotho is also present in 
mesolimbic regions of the brain that regulate reward behavior, including the ventral 
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tegmental area and nucleus accumbens, and FGF21 administration reduced tissue 
levels of dopamine and its metabolites in the nucleus accumbens (14). Thus, FGF21 
may act coordinately on multiple brain regions to regulate the consumption of both 
simple sugars and alcohol. 
 
In closing, our data linking β-Klotho to alcohol consumption together with previous 
GWAS data linking FGF21 to macronutrient preference raise the intriguing possibility of 
a liver-brain endocrine axis that plays an important role in the regulation of complex 
adaptive behaviors, including alcohol drinking. While our findings support an important 
role for the KLB gene in the regulation of alcohol drinking, we cannot rule out the 
possibility that KLB rs11940694 acts by affecting neighboring genes. Therefore 
additional genetic and mechanistic studies are warranted. Finally, it will be important to 
follow up on our findings in more severe forms of alcohol drinking, since our results 
suggest that this pathway could be targeted pharmacologically for reducing the desire 
for alcohol. 
 
Methods 
Alcohol phenotypes 
Alcohol intake in grams of alcohol per day was estimated by each cohort based on 
information about drinking frequency and type of alcohol consumed. For cohorts that 
collected data in ‘drinks per week’, standard ethanol contents in different types of 
alcohol drinks were provided as guidance to convert the data to ‘grams per week’, which 
was further divided by 7 to give intake as ‘grams per day’. Adjustment was made if 
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cohort-specific drink sizes differed from the standard. For cohorts that collected alcohol 
use in grams of ethanol per week, the numbers were divided by 7 directly into ‘grams 
per day’. Cohorts with only a categorical response to the question for drinks per week 
used mid-points of each category for the calculation. All non-drinkers (individuals 
reporting zero drinks per week) were removed from the analysis. The ‘grams per day’ 
variable was then log10 transformed prior to the analysis. Sex-specific residuals were 
derived by regressing alcohol in log10 (grams per day) in a linear model on age, age-
square, weight, and if applicable, study site and principal components to account for 
population structure. The sex-specific residuals were pooled and used as the main 
phenotype for subsequent analyses.  
 
Dichotomous alcohol phenotype was created based on categorization of ‘drinks per 
week’ variable. Heavy drinking was defined as >=21 drinks per week in men, or >=14 
drinks per week in women. Light (or zero) drinking was defined if male participants had 
<=14 drinks per week, or female participants had <=7 drinks per week. Drinkers having 
>14 to <21 drinks for men, or >7 to <14 drinks for women were excluded. Where 
information was available, current non-drinker who was former drinker of >14 drinker 
per week in men, and >7 drinks per week in women, as well as current non-drinker who 
was a former drinker of unknown amount were excluded; whereas current non-drinkers 
who were former drinkers of <=14 for men or <=7 for women were included.  Further 
exclusion was made if there were missing data on alcohol consumption or on the 
covariates. 
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The analyses only included participants of European origin and were performed 
in accordance with the principles expressed in the Declaration of Helsinki. Each cohort’s 
study protocol was reviewed and approved by their respective institutional review board 
and informed consent was obtained from all study subjects. 
 
Discovery GWAS in AlcGen and CHARGE+ and replication analyses 
Genotyping methods are summarized in Dataset S1B, S1C and S1F.  SNPs were 
excluded if: HWE P < 1x10-6 or based on cohort-specific criteria; MAF < 1%; imputation 
information score < 0.5; if results were only available from 2 or fewer cohorts, or total N 
< 10,000. Population structure was accounted for within cohorts via principal 
components analysis (PCA). Linkage disequilibrium (LD) score regression (24) was 
conducted on the GWAS summary results to examine the degree of inflation in test 
statistics, and genomic control correction was considered unnecessary (λGC=1.06 and 
intercept=1.00; λ=0.99 to 1.06 for individual cohorts, Dataset S1B and S1C). SNPs were 
taken forward for replication from discovery GWAS if they passed the above criteria and 
if they had P < 1x10-6 (one SNP with the smallest P taken forward in each region, 
except for AUTS2 for which two SNPs were taken forward based on previous results 
(7)). Meta-analyses were performed by METAL (25) or R (v3.2.2).  
 
Gene expression profiling in Framingham study 
In the Framingham study, gene expression profiling was undertaken for the blood 
samples of a total of 5,626 participants from the Offspring (N=2,446) at examination 
eight and the Third Generation (N=3,180) at examination two. Fasting peripheral whole 
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blood samples (2.5ml) were collected in PAXgene™ tubes (PreAnalytiX, 
Hombrechtikon, Switzerland). RNA expression profiling was conducted using the 
Affymetrix Human Exon Array ST 1.0 (Affymetrix, Inc., Santa Clara, CA) for samples 
that passed RNA quality control. The expression values for ~ 18,000 transcripts were 
obtained from the total 1.2 million core probe sets. Quality control procedures for 
transcripts have been described previously. All data used herein are available online in 
dbGaP (http://www.ncbi.nlm.nih.gov/gap; accession number phs000007). 
 
The cis-expression quantitative trait loci analysis in the Framingham study  
To investigate possible effects of rs11940694 in KLB on gene expression, we performed 
cis-eQTL analysis. The SNP in KLB was used as the independent variable in 
association analysis with the transcript of KLB measured using whole blood samples in 
the FHS (n=5,236). Affymetrix probe 2724308 was used to represent the KLB overall 
transcript levels. Age, sex, BMI, batch effects and blood cell differentials were included 
as covariates in the association analysis. Linear mixed model was used to account for 
familial correlation in association analysis.  
 
Mouse studies 
All mouse experiments were approved by the Institutional Animal Care and Research 
Advisory Committee of the University of Texas Southwestern Medical Center. Male 
littermates (2 to 4-month-old) maintained on a 12 hr light/dark cycle with ad libitum 
access to chow diet (Harlan Teklad TD2916) were used for all experiments. The Klb 
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gene was deleted from brain by crossing Klbfl/fl mice with Camk2a-Cre mice on a mixed 
C57BL/6J;129/Sv background as described (26). 
 
Alcohol drinking in mice 
For voluntary two-bottle preference experiments, male mice (n=9-13 per group) were 
given access to two bottles, one containing water and the other containing 2-16% 
ethanol (vol/vol) in water. After acclimation to the two-bottle paradigm, mice were 
exposed to each concentration of ethanol for 4 days. Total fluid intake (water + ethanol-
containing water), food intake and body weight were measured each day. Alcohol 
consumption (g) was calculated based on EtOH density (0.789 g/ml). To obtain 
accurate alcohol intake that corrected for individual differences in littermate size, alcohol 
consumption was normalized by body weight per day for each mouse. As a measure of 
relative alcohol preference, the preference ratio was calculated at each alcohol 
concentration by dividing total consumed alcohol solution (ml) by total fluid volume. 
Two-bottle preference assays were also performed with sucrose (0.5 and 5%) and 
quinine (2 and 20 mg/dl) solutions. For all experiments, the positions of the two bottles 
were changed every two days to exclude position effects.  
 
Mouse experiments with FGF21 
For FGF21 administration studies, recombinant human FGF21 protein provided by Novo 
Nordisk was administered at a dose of 0.7 mg/kg/day by subcutaneous osmotic mini-
pumps (Alzet 1004). Mice were single caged following mini-pump surgery, which was 
conducted under isoflurane anesthesia and 24 hour buprenorphine analgesia. Mice were 
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allowed to recover from mini-pump surgery for 4 days prior to alcohol drinking tests. 
After experiments, mice were sacrificed by decapitation and plasma was collected using 
EDTA or heparin after centrifugation for 15 minutes at 3000 rpm. Plasma FGF21 
concentrations were measured using the Biovendor FGF21 ELISA Kit according to 
manufacturer’s protocol. 
 
Plasma ethanol concentration and clearance 
For alcohol bioavailability tests, mice (n=4-5 per group) were injected i.p. with alcohol 
(2.0 g/kg, 20% w/vol) in saline, and tail vein blood was collected after 1 and 3 hours. 
Plasma alcohol concentrations were measured using the EnzyChrom™ Ethanol Assay 
Kit. 
 
Emotional behavior in mice 
For open field activity assays, naïve mice were placed in an open arena (44 x 44 cm, 
with the center defined as the middle 14 x 14 cm and the periphery defined as the area 
5 cm from the wall), and the amount of time spent in the center versus along the walls 
and total distance traveled were measured. For elevated plus maze activity assays, 
mice were placed in the center of a plus maze with 2 dark enclosed arms and 2 open 
arms. Mice were allowed to move freely around the maze, and the total duration of time 
in each arm and the frequency to enter both the closed and open arms was measured. 
For novelty suppression of feeding assays, mice fasted for 12 hours were placed in a 
novel environment and the time to approach and eat a known food was measured. 
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Statistical analysis 
All data are expressed as means ± S.E.M. Statistical analysis between the two groups 
was performed by unpaired two-tailed Student's t test using Excel or GraphPad Prism 
(GraphPad Software, Inc.). For multiple comparisons, one-way analysis of variance 
(ANOVA) with post-hoc Tukey was done using SPSS. 
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Figure Legends 
Figure 1. Genome-wide association results of log g/day alcohol in AlcGen and 
CHARGE+ consortia. (A) Manhattan plot showing the significance of the association (-
log10 transformed P value on the y axis) for each SNP at chromosomal position shown 
on the x axis. The dotted line represents the genome-wide significance level at P=5x10-
8. The genes that were followed up are labelled. (B) Quantile-quantile plot comparing 
the expected P value on the x axis and the observed P value on the y axis (both were -
log10 transformed). 
 
Figure 2: FGF21 reduces alcohol preference in mice by acting on β-Klotho in brain. (A) 
Alcohol preference ratios determined by two-bottle preference assays with water and 
the indicated ethanol concentrations for control (Klbfl/fl) and brain-specific β-Klotho 
knockout (KlbCamk2a) mice administered either FGF21 (0.7 mg/kg/day) or vehicle 
(n=10/ group). (B) Plasma ethanol and (C) FGF21 concentrations at the end of the 16% 
ethanol step of the two-bottle assay. (D) Plasma ethanol concentrations 1 and 3 hours 
after i.p. injection of 2 g/kg alcohol (n=4/each group). (E) Consumption of 16% ethanol 
(g/kg/d) and (F) alcohol preference ratios in two-bottle preferences assays performed 
with control (Klbfl/fl) and brain-specific β-Klotho-knockout (KlbCamk2a) mice. Alcohol 
preference was measured by volume of ethanol/total volume of fluid consumed 
(n=13/group). (G) Plasma ethanol concentrations 1 and 3 hours after i.p. injection of 2 
g/kg alcohol (n=5/group). Values are means ±S.E.M. For (A-C), *p<0.05; ***p<0.001 for 
Klbfl/fl + vehicle versus Klbfl/fl + FGF21 groups; and ##p<0.01; ###p<0.001 for Klbfl/fl + 
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FGF21 versus KlbCamk2a + FGF21 groups as determined by one-way ANOVA followed 
by Tukey's post-tests. For (E, F),*p<0.05 and **p<0.01. 
 
Figure 3: Behavior tests in brain-specific β-Klotho knockout mice. Results from (A) 
novelty suppressed feeding, (B) elevated plus maze and (C) open field activity assays 
performed with control (Klbfl/fl) and brain-specific β-Klotho-knockout (KlbCamk2a) mice 
(n=15/each group). Values are the time (seconds) spent for each step of the assay. 
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1. Cohort descriptions 
 
1.1 Population descriptions for GWAS discovery cohorts in the Alcohol 
Genome-wide Association (AlcGen) consortium 
 
Cohorte Lausannoise study (CoLaus) 
The cohort is a random population sample of the city of Lausanne aged 35-75 years. 
Recruitment began in June 2003 and ended in May 2006. The CoLaus study was 
approved by the Institutional Ethics Committee of the University of Lausanne and 
informed consent was appropriately obtained by all participants. All participants 
attended the outpatient clinic of the University Hospital of Lausanne in the morning 
after an overnight fast. Data were collected by trained field interviewers in a single 
visit lasting about 60 min. Alcohol consumption was assessed by questionnaire and 
measured in units per week. In total 3,121 individuals were included in the analysis. 
 
The Estonian Biobank Cohort (EGCUT) 
The Estonian Biobank Cohort is a population-based cohort of 52000 Estonian 
residents (81% ethnic Estonians), recruited on volunteer-basis in 2002-2010 
(www.biobank.ee), managed by the Estonian Genome Center, University of Tartu.   
 
The European Prospective Investigation of Cancer - Norfolk study (EPIC-
Norfolk) 
The EPIC-Norfolk sample includes 2,566 participants randomly selected from the 
EPIC-Norfolk Study, a population-based cohort study of 25,663 men and women of 
European descent aged 39-­‐79 years recruited in Norfolk, UK between 1993 and 
1997. 
 
The Erasmus Rucphen Family study (ERF) 
The ERF (1) is a family based study that includes over 3,000 participants descending 
from 22 couples living in the Rucphen region in the 19th century. All living 
descendants of these couples and their spouses were invited to take part in the 
study. The medical ethics committee of Erasmus MC constituted according to the 
WMO (National Act Medical-scientific research in human beings) approved the Study 
(MEC 213.575/2002/114). The genotyping for the ERF study was supported by 
EUROSPAN (European Special Populations Research Network) through the 
European Commission FP6 STRP grant (018947; LSHG-CT-2006-01947). The ERF 
study was further supported by grants from the Netherlands Organisation for 
Scientific Research (NWO), Erasmus MC, the Centre for Medical Systems Biology 
(CMSB1 and CMSB2) and the Netherlands Genomics Initiative (NGI) and also 
received funding from the European Community's Seventh Framework Programme 
(FP7/2007-2013)/grant agreement HEALTH-F4-2007-201413 by the European 
Commission under the program “Quality of Life and Management of the Living 
Resources” of 5th Framework Programme (no. QLG2-CT-2002-01254). High-
throughput analysis of the ERF data was supported by joint grant from Netherlands 
Organisation for Scientific Research and the Russian Foundation for Basic Research 
(NWO-RFBR 047.017.043). Exome sequencing analysis in ERF was supported by 
the ZonMw grant (project 91111025). 
 
The Fenland study (Fenland) 
The Fenland study is a population-based cohort study that uses objective measures 
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of disease exposure, such as accurate methods of body composition and energy 
expenditure, to study the interactions between genetic and lifestyle factors that 
cause obesity and diabetes. The volunteers are recruited from general practice lists 
in and around Cambridgeshire (Cambridge, Ely, and Wisbech) in the United 
Kingdom from birth cohorts from 1950–1975. 
 
The Younger Finnish Twin Cohort (FinnTwin12) 
The FinnTwin12 cohort is composed of twins born in Finland during 1983-87. The 
study has a two-stage sampling design. The larger, first-stage study is an 
epidemiological investigation of five consecutive and complete birth cohorts of 
Finnish twin children, including questionnaire assessments of both twins and parents 
at baseline, starting with a family questionnaire (returned by 2724 families, 87% 
participation rate) that was mailed late in the year before the twins reach age 12, with 
follow-up of all twins at age 14, 17.5 years and ~22. Nested within this 
epidemiological, population-based study, is the second-stage of FinnTwin12, an 
intensive assessment of a sub-sample of twin families. Most of the sub-sample was 
selected at random, but this random sample (~72%) was then enriched with twins at 
elevated familial risk for alcoholism. Genome-wide genotyping was performed on the 
subjects of the intensive sub-sample. 
 
The Older Finnish Twin Cohort (FinnTwinOld) 
This sample originates from the Older Finnish Twin Cohort. The 1975 , 1981 and 
1990 questionnaires for the same-sex twins and the 1996-97 questionnaires for 
opposite-sex twins requested identical information on the frequency and quantity of 
alcohol used during an average week (or month), the frequency of passouts 
experienced during the preceding year, and required a yes/no response to a 
question on drinking density. Frequency of alcohol use, measured as days' use per 
month on 5-point scales (“never” to “over 16 days a month”) was assessed 
separately for beer, wine, and spirits. Similarly, quantity was measured on three 7-
point scales, with the upper limits defined as consuming >48 bottles of beer (or 10 
bottles of wine) per week, or >20 bottles of spirits per month. Wine use did contribute 
to the consumption measure. For each type of beverage, consumption was 
converted into grams of absolute alcohol and summed to yield an estimate of total 
consumption in grams per month using the class midpoints of the categories and the 
average alcohol content of each beverage type. The script for computing alcohol 
amount is available from Jaakko Kaprio on request.     
 
The Helsinki Birth Cohort Study (HBCS) 
The Helsinki Birth Cohort Study (HBCS) is composed of 8,760 individuals born 
between the years 1934-44 in one of the two main maternity hospitals in Helsinki, 
Finland. Between 2001 and 2003, a randomly selected sample of 928 males and 
1075 females participated in a clinical follow-up study with a focus on cardiovascular, 
metabolic and reproductive health, cognitive function and depressive symptoms. 
 
The population-based Cooperative Health Research in the Region of Augsburg 
F3 Study (KORA F3)  
The population-based Cooperative Health Research in the Region of Augsburg 
(KORA) F3 Study was carried out in 2004-2005 as a follow-up of the MONICA/KORA 
S3 baseline study (1994-1995). In S3, 4,856 participants were recruited out of a 
randomized two-stage cluster sample of 6,640 subjects, with equal-sized sex- and 
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age-strata, from the target population of all German residents in the region of 
Augsburg aged 25–74 years. The F3 Study included 3,007 participants aged 35–84 
years. 1,644 randomly drawn participants aged 35–79 with Affymetrix genotype data 
and data on alcohol intake were included in the investigations reported. 
 
The population-based Cooperative Health Research in the Region of Augsburg 
F4 Study (KORA F4)  
The population-based Cooperative Health Research in the Region of Augsburg 
(KORA) F4 Study was carried out in 2006–2008 as a follow-up of the KORA S4 
baseline study (1999–2001). In S4, 4,261 participants were recruited out of a 
randomized two-stage cluster sample of 6,640 subjects, with equal-sized sex- and 
age-strata, from the target population of all German residents in the region of 
Augsburg aged 25-74 years. The F4 Study included 3,080 participants aged 32-81 
years. 1814 randomly drawn participants aged 32-81 with Affymetrix genotype data 
and data on alcohol intake were included in the investigations reported. 
 
LifeLines Cohort Study & Biobank (Lifelines) 
LifeLines is a multi-disciplinary prospective population-based cohort study examining 
in a unique three-generation design the health and health-related behaviors of 
165,000 persons living in the North East region of The Netherlands. It employs a 
broad range of investigative procedures in assessing the biomedical, socio-
demographic, behavioral, physical and psychological factors which contribute to the 
health and disease of the general population, with a special focus on multimorbidity 
and complex genetics. 
 
The London Life Sciences Prospective Population Study (LOLIPOP) 
LOLIPOP is a population based prospective study of 17,606 Indian Asian and 7,766 
European men and women aged 35-75 years, recruited from the lists of 58 General 
Practitioners in West London, United Kingdom between 2003 and 2008 (2, 3). 
Europeans were of self-reported white ancestry. Assessments of participants were 
carried out by trained research nurses with an interviewer-administered 
questionnaire. Anthropometric measurements and blood samples were taken on site. 
Alcohol consumption was measured in units per week. One unit is equivalent to: a 
small glass of wine, a single pub measure of spirits, or half a pint of beer/lager. 
Aliquots of whole blood were stored at -80C and DNA was extracted and genotyping 
was carried out thereafter.  The LOLIPOP study is approved by the local Research 
Ethics Committees (3). All participants provided written consent for the study.  
 
The Netherlands Study of Depression and Anxiety (NESDA) 
The Netherlands Study of Depression and Anxiety (NESDA)	  (4), an ongoing cohort 
study into the long-term course and consequences of depressive and anxiety 
disorders. Briefly, in 2004-2007 participants aged 18 to 65 years were recruited from 
the community (19%), general practice (54%) and secondary mental health care 
(27%), reflecting therefore various settings and developmental stages of 
psychopathology in order to obtain a full and generalizable picture of the course of 
psychiatric disorders. A total of 2,981 participants were included, consisting of 
persons with a current or past depressive and/or anxiety disorder and healthy 
controls. The research protocol was approved by the ethical committee of 
participating universities, and all respondents provided written informed consent.  
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The Northern Finland Birth Cohort 1966 (NFBC1996) 
The North Finland Birth Cohort of 1966 (NFBC1966, n=12,058 live born) was 
designed to study factors affecting preterm birth, low birth weight, and subsequent 
morbidity and mortality (http://kelo.oulu.fi/NFBC/). The longitudinal data collection 
includes clinical examination and blood sampling at age 31 years, from which data in 
the current study are drawn. The attendees in the follow-up (71% response rate) 
were adequately representative of the original cohort as is the final study sample in 
the present analyses. A total of 4,763 genotyped samples were available from the 
NFBC1966. 
 
Netherlands Twin Register cohort (NTR) 
Netherlands Twin Register (NTR)	  (5, 6) participants are ascertained based of the 
presence of twins or triplets in the family and consist of multiples, their parents, 
siblings and spouses. Twins are born in all strata of society and NTR represents a 
general sample from the Dutch population.  
 
The Australian twin-family study of alcohol use disorder (OZALC) 
This twin/family cohort was based on two groups of twins, born before 1964 and born 
1964-71, enrolled in a voluntary Australia-wide twin registry.  Twins, their spouses, 
and first-degree relatives were recruited for a study on alcohol dependence and 
related phenotypes (7). Alcohol intake in the week preceding blood collection was 
self-reported, and history of alcohol use and dependence was obtained through 
structured telephone interviews. 
 
The Prevention of REnal and Vascular ENd-stage Disease study (PREVEND) 
The PREVEND study is an ongoing prospective study investigating the natural 
course of increased levels of urinary albumin excretion and its relation to renal and 
cardiovascular disease. Inhabitants 28 to 75 years of age (n=85,421) in the city of 
Groningen, The Netherlands, were asked to complete a short questionnaire, 47% 
responded, and individuals were then selected with a urinary albumin concentration 
of at least 10 mg/L (n = 7,768) and a randomly selected control group with a urinary 
albumin concentration less than 10 mg/L (n = 3,395). 
 
The Study of Health in Pomerania (SHIP) 
The Study of Health in Pomerania (SHIP) is a population-based project in West 
Pomerania, the north-east area of Germany (8, 9). A sample from the population 
aged 20 to 79 years was drawn from population registries. First, the three cities of 
the region (with 17,076 to 65,977 inhabitants) and the 12 towns (with 1,516 to 3,044 
inhabitants) were selected, and then 17 out of 97 smaller towns (with less than 1,500 
inhabitants), were drawn at random. Second, from each of the selected communities, 
subjects were drawn at random, proportional to the population size of each 
community and stratified by age and gender. Only individuals with German 
citizenship and main residency in the study area were included. Finally, 7,008 
subjects were sampled, with 292 persons of each gender in each of the twelve five-
year age strata. In order to minimize drop-outs by migration or death, subjects were 
selected in two waves. The net sample (without migrated or deceased persons) 
comprised 6,267 eligible subjects. Selected persons received a maximum of three 
written invitations. In case of non-response, letters were followed by a phone call or 
by home visits if contact by phone was not possible. The SHIP population finally 
comprised 4,308 participants (corresponding to a final response of 68.8%). Alcohol 
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intake was assessed by questionnaire, including drink-specific quantity-frequency 
over 30 days (10).  
 
TwinsUK 
TwinsUK is based on a sample of 5,654 individuals from the UK. Among these, 
3,471 have been genotyped and have data on alcohol intake assessed by self-
reported questionnaire, and 1,204 represent one co-twin per family which have been 
genotyped and have data on alcohol intake assessed by self-reported questionnaire.  
 
The Cardiovascular Risk in Young Finns Study (YFS) 
The YFS is a population-based follow up-study started in 1980. The main aim of the 
YFS is to determine the contribution made by childhood lifestyle, biological and 
psychological measures to the risk of cardiovascular diseases in adulthood. In 1980, 
over 3,500 children and adolescents all around Finland participated in the baseline 
study. The follow-up studies have been conducted mainly with 3-year intervals. The 
27-year follow-up study was conducted in 2007 (ages 30-45 years) with 2,204 
participants. The study was approved by the local ethics committees (University 
Hospitals of Helsinki, Turku, Tampere, Kuopio and Oulu) and was conducted 
following the guidelines of the Declaration of Helsinki. All participants gave their 
written informed consent. 
 
 
 
1.2 Population descriptions for GWAS discovery cohorts in the Heart and 
Aging Research in Genomic Epidemiology Plus (CHARGE+) Consortium 
 
Age, Gene/Environment Susceptibility–Reykjavik (AGES-Reykjavik) 
The AGES-Reykjavik Study (11) is a single center prospective cohort study based on 
the Reykjavik Study. The Reykjavik Study was initiated in 1967 by the Icelandic 
Heart Association to study cardiovascular disease and risk factors. The cohort 
included men and women born between 1907 and 1935 who lived in Reykjavik at the 
1967 baseline examination. Re-examination of surviving members of the cohort was 
initiated in 2002 as part of the AGES-Reykjavik Study.  
 
The Atherosclerosis Risk in Communities Study (ARIC) 
The ARIC study (12) consists of a prospective cohort designed to identify the causes 
and outcomes of cardiovascular disease in 15,792 individuals from 4 communities 
(Forsyth County, NC; Jackson, MS; suburbs of Minneapolis, MN; and Washington 
County, MD). ARIC study participants underwent interviews, fasting venipuncture, 
and measurement of anthropometrics at the baseline and follow-up examinations. 
Trained interviewers ascertained basic demographic data, medical history, and 
information about personal diet habits.  A full description of study design is available 
on the ARIC website (http://www2.cscc.unc.edu/aric/). In total, 4,106 individuals had 
both genotyping and alcohol phenotype. Alcohol consumption was ascertained by 
means of an interviewer-administered dietary questionnaire. Frequency of alcohol 
consumption was determined as usual weekly intake, with the amount of alcohol 
consumed in grams per week calculated assuming different serving sizes and 
alcohol content for beer, wine, and hard liquor. Serving sizes and alcohol content 
were defined as follows: ‘one beer' (12 oz. bottles or cans of beer, 13.2 g), 'one glass 
of wine' (4 oz. glass, 10.8 g), or ‘one shot of liquor or one mixed drink' (1.5 oz. shot 
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of hard liquor, 15.1 g). The total amount of absolute alcohol ingested weekly for past 
alcohol consumption was determined by multiplying the number of servings by the 
amount of alcohol in one serving of the type of alcohol ordinarily drunk. If more than 
one type was ordinarily drunk, the calculation was made assuming an equal number 
of drinks of each type. The total amount of absolute alcohol ingested weekly for 
present alcohol consumption resulted from the addition of absolute alcohol 
consumed for wine, beer, and hard liquor. The total amount of absolute alcohol 
drunk during the 24 hours prior to the clinic interview was determined by multiplying 
the number of drinks by the amount of absolute alcohol in the type of drink 
consumed. For a drinker who reported less than one drink per week, the alcohol 
consumption was recorded as zero grams per week. All questions were closed-
ended and designed for direct data entry by a trained interviewer. In order to ensure 
standardization, exact wording and order of questions were followed. Questions 
were skipped only if specified in the questionnaire instructions. 
 
The Cardiovascular Health Study (CHS) 
The CHS is a population-based cohort study of risk factors for coronary heart 
disease and stroke in adults ≥65 years conducted across four field centers (13). The 
original predominantly European ancestry cohort of 5,201 persons was recruited in 
1989-1990 from random samples of the Medicare eligibility lists; subsequently, an 
additional predominantly African-American cohort of 687 persons was enrolled for a 
total sample of 5,888. The CHS GWAS, which had the primary aim of studying 
incident cardiovascular events, focused on 3,980 participants who were free of 
clinical cardiovascular disease at study baseline, consented to genetic testing, and 
had DNA available for genotyping. A total of 1,908 persons were excluded from the 
GWAS study sample due to the presence at study baseline of coronary heart 
disease, congestive heart failure, peripheral vascular disease, valvular heart 
disease, stroke, or transient ischemic attack. Because the other cohorts were 
predominantly of European descent, the African American participants were 
excluded from this analysis. In total, 3009 participants with both genotype and 
alcohol phenotype were included in the analyses. 
At the baseline visit and annually, participants separately reported their usual 
frequency of consumption of beer, wine, and liquor, and the usual number of 12-
ounce cans or bottles of beer, 6-ounce glasses of wine, and shots of liquor that they 
drank on each occasion.  The full text of the CHS nutritional questionnaire is publicly 
available (http://www.chs-nhlbi.org/forms/r25p3.htm).  At baseline, participants also 
reported whether they changed their pattern of consumption during the past 5 years 
and whether they ever regularly consumed 5 or more drinks daily. 
 
The Framingham Heart Study (FHS) 
The FHS sample includes the Framingham Heart Study Offspring (14) and the third 
generation (15) cohorts. In 1971, children and spouses of children of the original 
FHS cohort participants were recruited into the Framingham offspring cohort, which 
consists of 5,124 men and women. The FHS offspring participants have been 
examined every four to eight years unless specified otherwise, common clinical 
phenotypes from all examinations were available for this investigation. From 2002 to 
2005, a third generation cohort of 4,095 individuals was recruited to the FHS.  The 
third generation cohort (n=4,095) includes children and spouses of children of the 
Offspring cohort. In total, 8,955 individuals had both genotyping and alcohol 
phenotype.  
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Alcohol consumption was assessed via questionnaire at the study examination 
closest to the time point of DNA collection.   
 
The Health, Aging, and Body Composition (HABC) 
The Health ABC study (16) is a prospective cohort study investigating the 
associations between body composition, weight-related health conditions, and 
incident functional limitation in older adults.  Health ABC enrolled well-functioning, 
community-dwelling black (n=1281) and white (n=1794) men and women aged 70-79 
years between April 1997 and June 1998.  Participants were recruited from a 
random sample of white and all black Medicare eligible residents in the Pittsburgh, 
PA, and Memphis, TN, metropolitan areas.  Participants have undergone annual 
exams and semi-annual phone interviews.  The current study sample consists of 
1559 white participants who attended the second exam in 1998-1999 with available 
genotyping data.   
Alcohol consumption at baseline was assessed by asking the participant how many 
alcoholic drinks he/she consumed in a typical week, during the past 12 months. 
Furthermore, it was asked whether a person ever drank more than what he/she 
typically drank in the past 12 months. 
 
The Multi-Ethnic Study of Atherosclerosis (MESA) 
The MESA is a study of the characteristics of subclinical cardiovascular disease 
(disease detected non-invasively before it has produced clinical signs and 
symptoms) and the risk factors that predict progression to clinically overt 
cardiovascular disease or progression of the subclinical disease (17). MESA 
researchers study a diverse, population-based sample of 6,814 asymptomatic men 
and women aged 45-84. Thirty-eight percent of the recruited participants are White, 
28 percent African-American, 22 percent Hispanic, and 12 percent Asian, 
predominantly of Chinese descent. Participants were recruited from six field centers 
across the United States: Wake Forest University, Columbia University, Johns 
Hopkins University, University of Minnesota, Northwestern University and University 
of California, Los Angeles. The current analysis was limited to n=1596 White 
participants with data available on alcohol consumption through the Food-frequency 
questionnaire. Data on alcoholic beverage consumption (drinks/day) were obtained 
on 2,382 Caucasian individuals with genotypes available through MESA SHARe.  As 
a part of a 120-item food frequency questionnaire, participants were asked the 
frequency they consumed each beer, wine, and liquor or mixed drinks (9 frequency 
options ranging from rarely/never to six or more drinks/day) (18, 19). Responses to 
these three line items were summed to estimate total alcoholic drinks consumed 
each day. 
 
The Rotterdam Study (RS) 
The RS (20) is a prospective, population-based study from the well-defined district of 
Ommoord within the city of Rotterdam, designed to investigate the occurrence and 
determinants of diseases in the elderly. The cohort was initially defined in 1990 
among 7 983 persons who underwent a home interview and extensive physical 
examination at baseline and during follow-up examinations occurring every 3-4 years 
(RS-I). The cohort was further extended in 2000 (RS-II) and 2005 (RS-III), 
establishing a total of 14926 participants.  
 
The Women’s Genome Health Study (WGHS) 
9	  
	  
The WGHS (21) is a prospective cohort of initially healthy, female North American 
health care professionals at least 45 years old at baseline in 1992-1994, 
representing participants in the Women’s Health Study (WHS) who provided a blood 
sample at baseline and consent for blood-based analyses.  These WHS was 2x2 
randomized, placebo controled trial of aspirin and vitamin E in prevention of 
cardiovascular disease and cancer over 10 years. Since the end of the trial, follow-
up in the WHS/WGHS has continued in observational mode. 
 
	  
	  
1.3 Population descriptions for replication cohorts 
 
Airwave Health Monitoring Study (Airwave) 
The Airwave Health Monitoring Study (22) was established to evaluate possible 
health risks associated with use of TETRA, a digital communication system used by 
police forces and other emergency services in Great Britain since 2001. The study 
has been broadened to investigate more generally the health of the work force. From 
2004, participants from each force who agreed to participate were enrolled either 
with an enrolment questionnaire or a comprehensive health screening performed 
locally. This includes questionnaire, 7-day food diaries, anthropometry, 
measurements of cardiovascular and cognitive function, blood chemistry, 
coagulation and hematology. By March 2015, the study had recruited 53,606 
participants, of whom 45,433 had attended the health screening. 12,930 participants 
with genotype data were included in this analysis. 
 
The Austrian Stroke Prevention Study (ASPS)  
The ASPS study is a single center prospective follow-up study on the effects of 
vascular risk factors on brain structure and function in the normal elderly population 
of the city of Graz, Austria. The procedure of recruitment and diagnostic work-up of 
study participants has been described previously (23, 24). A total of 2,007 
participants were randomly selected from the official community register stratified by 
gender and 5 year age groups. Individuals were excluded from the study if they had 
a history of neuropsychiatric disease, including previous stroke, transient ischemic 
attacks, and dementia, or an abnormal neurologic examination determined on the 
basis of a structured clinical interview and a physical and neurologic examination. 
During 2 study periods between September 1991 and March 1994 and between 
January 1999 and December 2003 an extended diagnostic work-up including 
neuropsychological testing was done in 1,076 individuals aged 45 to 85 years 
randomly selected from the entire cohort: 509 from the first period and 567 from the 
second. In 1992, blood was drawn from all study participants for DNA extraction. 
They were all European Caucasians. Genotyping was performed in 996 participants, 
and those 829 who passed genotyping quality control and have data on alcohol 
intake were available for these analyses.  
 
The British 1958 birth cohort (B58C) 
The British 1958 birth cohort (25) is a follow-up study of persons born throughout 
England, Scotland and Wales one week in March 1958. Alcohol consumption was 
self-reported at a biomedical examination at age 44-45 years, at which blood 
sampling was performed with consent for DNA extraction and creation of 
immortalized cell lines. Genotyping of three non-overlapping subsets of the cohort 
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was performed by the Wellcome Trust Case-Control Consortium, the Type 1 
Diabetes Genetics Consortium and the GABRIEL Asthma Genetics Consortium. The 
three subsets were combined for imputation using the 1000-genomes phase 1 
reference panel, and for subsequent statistical analysis. 
 
Data from an Epidemiological Study on the Insulin Resistance syndrome 
(DESIR) 
General population from ten French Social Security Health Examination Centers. 
 
The Finnish Twin Cohort replication sample (FinnTwin replication) 
Sample used for replication consists of subjects from the Older Finnish Twin Cohort 
and the Younger Finnish Twin Cohorts (non-overlapping with the discovery sample). 
Please see cohort descriptions of the discovery sample. 
 
Genetic Regulation of Arterial Pressure of Humans in the Community Study 
(GRAPHIC)  
The GRAPHIC Study comprises 2024 individuals from 520 nuclear families recruited 
from the general population in Leicestershire, UK between 2003-2005 for the 
purpose of investigating the genetic determinants of blood pressure and related 
cardiovascular traits. Families were included if both parents aged 40-60 years and 
two offspring ≥18 years wished to participate. A detailed medical and lifestyle history 
including alcohol intake was obtained from study subjects by standardized 
questionnaires and clinical examination was performed by research nurses following 
standard procedures. 
 
Generation Scotland: Scottish Family Health Study (GS:SFHS) 
GS:SFHS (26) consists of 23,960 individuals recruited at random from general 
medical practices across Scotland, 21,516 of these attended the research clinic. 
Eligibility criteria specified that participants were over 18 years of age and had one 
first-degree relative also willing to participate. Genome-wide SNP data were 
ascertained for 10,000 individuals, and after quality control, genotype data were 
available for 9,863 participants, which are the participants used in this study. 7,281 
of these individuals self-reported as currently consuming alcohol. Alcohol 
consumption was assessed using a pre-clinical questionnaire. Participants were 
identified as current drinkers, former drinkers or never drinkers. Consumption was 
measured in self-reported units of alcohol consumed in the previous week. The 
cohort has been described in further detail elsewhere (26). 
 
The INGI - Carlantino study (INGI_CARL) 
This cohort comprises the samples coming from a small village from the southern 
region of Italy Puglia. For all samples a wide range of information are available 
including alcohol intake and anthropometric measurements. Moreover for all 
samples a DNA sample was acquired and was used for genotyping with high density 
SNP arrays. 
 
The INGI - Friuli Venezia Giulia study (INGI_FVG) 
This cohort comprises the samples coming from a 6 small villages from the northern 
region of Italy Friuli Venezia Giulia. For all samples a wide range of information are 
available including alcohol intake and anthropometric measurements. Moreover for 
all samples a DNA sample was acquired and was used for genotyping with high 
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density SNP arrays. 
 
The INGI-­‐Val Borbera study (INGI_VB) 
The INGI-­‐Val Borbera population is a collection of 1,785 genotyped samples 
collected in the Val Borbera Valley, a geographically isolated valley located within 
the Appenine Mountains in Northwest Italy. 
 
The Lothian Birth Cohort 1921 (LBC1921) 
LBC1921 consists of 550 (234 male) relatively healthy individuals, assessed on 
cognitive and medical traits at a mean age of 79.1 years (SD = 0.6). They were born 
in 1921, most took part in the Scottish Mental Survey of 1932, and almost all lived 
independently in the Lothian region (Edinburgh City and surrounding area) of 
Scotland. Data on alcohol intake is available. 
 
The Lothian Birth Cohort 1936 (LBC1936) 
LBC1936 consists of 1091 (548 male) relatively healthy individuals who underwent 
cognitive and medical testing at a mean age of 69.6 years (SD = 0.8). They were 
born in 1936, most took part in the Scottish Mental Survey of 1947, and almost all 
lived independently in the Lothian region of Scotland. Data on alcohol intake is 
available. 
 
The Northern Swedish Population Health Study (NSPHS) 
The NSPHS was initiated in 2006 to provide a health survey of the population in the 
parish of Karesuando, county of Norrbotten, Sweden, and to study the medical 
consequences of lifestyle and genetics. This parish has about 1,500 inhabitants who 
meet the eligibility criteria in terms of age (≥15 years), of which 1066 individuals 
participated in the study. 
 
The Orkney Complex Disease Study (ORCADES) 
The Orkney Complex Disease Study (ORCADES) is a family-based study of 2078 
individuals with ancestry from the isolated Scottish archipelago of Orkney. Fasting 
blood samples were collected and over 300 health-related phenotypes and 
environmental exposures were measured in each individual. All participants gave 
informed consent and the study was approved by Research Ethics Committees in 
Orkney and Aberdeen. 
 
The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) 
All data come from the PROspective Study of Pravastatin in the Elderly at Risk 
(PROSPER). A detailed description of the study has been published elsewhere. 
PROSPER was a prospective multicenter randomized placebo-controlled trial to 
assess whether treatment with pravastatin diminishes the risk of major vascular 
events in elderly. Between December 1997 and May 1999, we screened and 
enrolled subjects in Scotland (Glasgow), Ireland (Cork), and the Netherlands 
(Leiden). Men and women aged 70-82 years were recruited if they had pre-existing 
vascular disease or increased risk of such disease because of smoking, 
hypertension, or diabetes. A total number of 5,804 subjects were randomly assigned 
to pravastatin or placebo. A large number of prospective tests were performed 
including Biobank tests and cognitive function measurements. 
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Council. 
ERF  We are grateful to all study participants and their relatives, 
general practitioners and neurologists for their contributions and 
to P. Veraart for her help in genealogy, J. Vergeer for the 
supervision of the laboratory work and P. Snijders for his help in 
data collection. The genotyping for the ERF study was supported 
by EUROSPAN (European Special Populations Research 
Network) through the European Commission FP6 STRP grant 
(018947; LSHG-CT-2006-01947). The ERF study was further 
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supported by grants from the Netherlands Organisation for 
Scientific Research (NWO), Erasmus MC, the Centre for Medical 
Systems Biology (CMSB1 and CMSB2) and the Netherlands 
Genomics Initiative (NGI) and also received funding from the 
European Community's Seventh Framework Programme 
(FP7/2007-2013)/grant agreement HEALTH-F4-2007-201413 by 
the European Commission under the program “Quality of Life and 
Management of the Living Resources” of 5th Framework 
Programme (QLG2-CT-2002-01254). High-throughput analysis of 
the ERF data was supported by joint grant from Netherlands 
Organisation for Scientific Research and the Russian Foundation 
for Basic Research (NWO-RFBR 047.017.043). Exome 
sequencing analysis in ERF was supported by the ZonMw grant 
(project 91111025). Najaf Amin was supported by the 
Netherlands Brain Foundation (project number F2013(1)-28). 
Exome sequencing analysis in ERF was supported by the ZonMw 
grant (project 91111025). 
Fenland  We are grateful to all the volunteers for their time and help, and to 
the General Practitioners and practice staff for assistance with 
recruitment. We thank the Fenland Study Investigators, Fenland 
Study Co-ordination team and the Epidemiology Field, Data and 
Laboratory teams. The Fenlund Study was funded by the Medical 
Research Council (MC_U106179471) 
FinnTwin12 We warmly thank the participating twin pairs and their family 
members for their contribution. We express our appreciation to 
the skilled study interviewers A-M Iivonen, K Karhu, H-M Kuha, U 
Kulmala-Gråhn, M Mantere, K Saanakorpi, M Saarinen, R Sipilä, 
L Viljanen and E Voipio. Anja Häppölä and Kauko Heikkilä are 
acknowledged for their valuable contribution in recruitment, data 
collection, and data management. Antti-Pekka Sarin and Samuli 
Ripatti are acknowledged for genotype data quality controls and 
imputation. Phenotyping and genotyping of the Finnish twin 
cohorts was supported by the Academy of Finland Center of 
Excellence in Complex Disease Genetics (grants 213506, 
129680), the Academy of Finland (grants 100499, 205585, 
118555, 141054, 265240, 263278 and 264146 to J. Kaprio), 
National Institute of Alcohol Abuse and Alcoholism (grants AA-
12502, AA-00145, and AA-09203 to R. J. Rose and AA15416 and 
K02AA018755 to D. M. Dick), and the Welcome Trust Sanger 
Institute, UK.  
FinnTwinOld_1 We warmly thank the participating twin pairs and their family 
members for their contribution. We express our appreciation to 
the skilled study interviewers A-M Iivonen, K Karhu, H-M Kuha, U 
Kulmala-Gråhn, M Mantere, K Saanakorpi, M Saarinen, R Sipilä, 
L Viljanen and E Voipio. Anja Häppölä and Kauko Heikkilä are 
acknowledged for their valuable contribution in recruitment, data 
collection, and data management. Antti-Pekka Sarin and Samuli 
Ripatti are acknowledged for genotype data quality controls and 
imputation. Phenotyping and genotyping of the Finnish twin 
cohorts was supported by the Academy of Finland Center of 
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129680), the Academy of Finland (grants 100499, 205585, 
118555, 141054, 265240, 263278 and 264146 to J. Kaprio), 
Global Research Award for Nicotine Dependence, Pfizer Inc. (to 
J. Kaprio), and the Welcome Trust Sanger Institute, UK.  
FinnTwinOld_2 We warmly thank the participating twin pairs and their family 
members for their contribution. We express our appreciation to 
the skilled study interviewers A-M Iivonen, K Karhu, H-M Kuha, U 
Kulmala-Gråhn, M Mantere, K Saanakorpi, M Saarinen, R Sipilä, 
L Viljanen and E Voipio. Anja Häppölä and Kauko Heikkilä are 
acknowledged for their valuable contribution in recruitment, data 
collection, and data management. The DNA extractions, sample 
quality controls, biobank upkeep and aliquotting were performed 
in the National Public Health Institute, Helsinki, Finland. The 
Finnish Twin Cohort study received financial support from the 
Academy of Finland Center of Excellence in Complex Disease 
Genetics, ENGAGE project and grant agreement HEALTH-F4-
2007-201413 and the GenomeEUtwin project, which was 
supported by the European Commission under the program 
’Quality of Life and Management of the Living Resources’ of 5th 
Framework Program (QLG2-CT-2002-01254).  
FinnTwinOld_3 We warmly thank the participating twin pairs and their family 
members for their contribution. We express our appreciation to 
the skilled study interviewers A-M Iivonen, K Karhu, H-M Kuha, U 
Kulmala-Gråhn, M Mantere, K Saanakorpi, M Saarinen, R Sipilä, 
L Viljanen and E Voipio. Anja Häppölä and Kauko Heikkilä are 
acknowledged for their valuable contribution in recruitment, data 
collection, and data management. Antti-Pekka Sarin and Samuli 
Ripatti are acknowledged for genotype data quality controls and 
imputation. Phenotyping and genotyping of the Finnish twin 
cohorts was supported by the Academy of Finland Center of 
Excellence in Complex Disease Genetics (grants 213506, 
129680), the Academy of Finland (grants 100499, 205585, 
118555, 141054, 265240, 263278 and 264146 to J. Kaprio), and 
the Welcome Trust Sanger Institute, UK.  
HBCS  We thank all study participants as well as everybody involved in 
the Helsinki Birth Cohort Study. The Helsinki Birth Cohort Study 
was supported by grants from the Academy of Finland, the 
Finnish Diabetes Research Society, Folkhälsan Research 
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Ministry of Education, Ahokas Foundation, Emil Aaltonen 
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F4  
The KORA study was initiated and financed by the Helmholtz 
Zentrum München – German Research Center for Environmental 
Health, which was funded by the German Federal Ministry of 
Education and Research (BMBF) and by the State of Bavaria. 
Furthermore, KORA research was supported within the Munich 
Center of Health Sciences (MC-Health), Ludwig-Maximilians-
Universität, as part of LMUinnovativ. 
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Health Research (NIHR) Comprehensive Biomedical Research 
Centre Imperial College Healthcare NHS Trust. The work was 
carried out in part at the NIHR/Wellcome Trust Imperial Clinical 
Research Facility. We thank the participants and research staff 
who made the study possible. The LOLIPOP study was funded by 
the British Heart Foundation (SP/04/002), the Medical Research 
Council (G0601966, G0700931), the Wellcome Trust 
(084723/Z/08/Z), the NIHR (RP-PG-0407-10371), European 
Union FP7 (EpiMigrant, 279143) and Action on Hearing Loss 
(G51). 
NESDA  Studies were supported by Netherlands Organization for Scientific 
Research (Geestkracht program grant 10-000-1002); the Center 
for Medical Systems Biology (CSMB, NWO Genomics); 
Biobanking and Biomolecular Resources Research Infrastructure 
(BBMRI-NL); VU University’s Institutes for Health and Care 
Research (EMGO+) and Neuroscience Campus Amsterdam, 
University Medical Center Groningen, Leiden University Medical 
Center, National Institutes of Health (NIH, R01D0042157-01A, 
MH081802, Grand Opportunity grants 1RC2 MH089951 and 
1RC2 MH089995). Genotyping and analyses were partly funded 
by the Genetic Association Information Network (GAIN) of the 
Foundation for the National Institutes of Health. Computing was 
supported by BiG Grid, the Dutch e-Science Grid, which was 
supported by NWO. 
NFBC1966  We thank the late Professor Paula Rantakallio for launching 
NFBCs), and Ms. Outi Tornwall and Ms. Minttu Jussila for DNA 
biobanking. The authors also acknowledge the contribution of the 
late Academian of Science Leena Peltonen. NFBC1966 received 
financial support from the Academy of Finland (grants 104781, 
120315, 129269, 1114194, 24300796, Center of Excellence in 
Complex Disease Genetics and SALVE), University Hospital 
Oulu, Biocenter, University of Oulu, Finland (75617), NHLBI grant 
5R01HL087679-02 through the STAMPEED program 
(1RL1MH083268-01), NIH/NIMH (5R01MH63706:02), ENGAGE 
project and grant agreement  HEALTH-F4-2007-201413, EU FP7 
EurHEALTHAgeing-277849, the Medical Research Council, UK 
(G0500539, G0600705, G1002319,  PrevMetSyn/SALVE) and the 
MRC, Centenary Early Career Award. The program is funded by 
the H2020-633595 DynaHEALTH action and academy of Finland 
EGEA-project (285547). The DNA extractions, sample quality 
controls, biobank up-keeping and aliquotting was performed in the 
National Public Health Institute, Biomedicum Helsinki, Finland and 
supported financially by the Academy of Finland and Biocentrum 
Helsinki. 
NTR  The study was supported by Netherlands Scientific Organization 
(NWO), grant 480-05-003; Netherlands Organization for Scientific 
Research, grants ZonMW (Addiction program) 31160008, ZonMW 
940-37-024, NWO/SPI 56-464-14192, NWO-400-05-717, NWO-
MW 904-61-19, NWOMagW 480-04-004; European Research 
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Council ERC-230374 and ERC-284167; Centre for Medical 
Systems Biology (NWO Genomics); Netherlands Bioinformatics 
Center/BioAssist/RK/2008.024; National Institute of Mental Health 
(NIH) MH081802, 1RC2 MH089951, 1RC2 MH089995; National 
Institute of Mental Health, Grant number RC2 MH089951. 
OZALC  We acknowledge the contribution of the participants in this study, 
and the work of the interviewers and laboratory staff at QIMR 
Berghofer Medical Research Institute in obtaining the phenotype 
information and genotypes. We also acknowledge the 
contributions of Dr. Grant Montgomery and Ms Anjali Henders to 
project management, sample acquisition and genotyping. Aspects 
of the data collection and genotyping were made possible by 
grants to Dr. Pamela AF Madden and to the late Dr. Richard 
Todd. The study was supported by National Institutes of Health 
grants AA07535,AA07728, AA13320, AA13321, AA14041, 
AA11998, AA17688,DA012854, and DA019951; by grants from 
the Australian National Health and Medical Research Council 
(241944, 339462, 389927,389875, 389891, 389892, 389938, 
442915, 442981, 496739, 552485, and 552498) and the 
Australian Research Council(A7960034, A79906588, A79801419, 
DP0770096, DP0212016, and DP0343921); and by the 5th 
Framework Programme (FP-5) GenomEUtwin Project (QLG2-CT-
2002-01254). Genome-wide genotyping at the Center for 
Inherited Disease Research was supported by a grant to the late 
Richard Todd, M.D., Ph.D. GWM was supported by the National 
Health and Medical Research Council Fellowship Scheme. 
PREVEND  PREVEND genetics was supported by the Dutch Kidney 
Foundation (Grant E033), the EU project grant GENECURE (FP-6 
LSHM CT 2006 037697), the National Institutes of Health (grant 
2R01LM010098), The Netherlands Organisation for Health 
Research and Development (NWO-Groot grant 
175.010.2007.006, NWO VENI grant 916.761.70, ZonMw grant 
90.700.441), and the Dutch Inter University Cardiology Institute 
Netherlands (ICIN). N.Verweij was supported by ICIN-NHI and 
Marie Sklodowska-Curie GF (call: H2020-MSCA-IF-2014, Project 
ID: 661395) 
SHIP  SHIP is part of the Community Medicine Research net of the 
University of Greifswald, Germany, which was funded by the 
Federal Ministry of Education and Research (grants 01ZZ9603, 
01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs as well 
as the Social Ministry of the Federal State of Mecklenburg-West 
Pomerania, and the network ‘Greifswald Approach to 
Individualized Medicine (GANI_MED)’ funded by the Federal 
Ministry of Education and Research (grant 03IS2061A). Genome-
wide data have been supported by the Federal Ministry of 
Education and Research (grant 03ZIK012) and a joint grant from 
Siemens Healthcare, Erlangen, Germany and the Federal State of 
Mecklenburg- West Pomerania. The University of Greifswald is a 
member of the Caché Campus program of the InterSystems 
GmbH. 
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TwinsUK  We are grateful to all the twins who took part in this study, the 
midwives for recruiting them and the whole TwinsUK team, which 
includes interviewers, computer and laboratory technicians, 
clerical workers, research scientists, volunteers, managers, 
receptionists and nurses. SNP Genotyping was performed by The 
Wellcome Trust Sanger Institute and National Eye Institute via 
NIH/CIDR. The study was funded by the Wellcome Trust; 
European Community’s Seventh Framework Programme 
(FP7/2007-2013). The study also received support from the 
National Institute for Health Research (NIHR)-funded 
BioResource, Clinical Research Facility and Biomedical Research 
Centre based at Guy’s and St Thomas’ NHS Foundation Trust in 
partnership with King’s College London.  
YFS  We thank Ville Aalto for expert technical assistance in the 
statistical analyses and Irina Lisinen. The Young Finns Study was 
supported by the Academy of Finland: grants 286284, 134309 
(Eye), 126925, 121584, 124282, 129378 (Salve), 117787 (Gendi), 
and 41071 (Skidi); the Social Insurance Institution of Finland; 
Kuopio, Tampere and Turku University Hospital Medical Funds; 
Juho Vainio Foundation; Paavo Nurmi Foundation; Finnish 
Foundation of Cardiovascular Research; Finnish Cultural 
Foundation; Tampere Tuberculosis Foundation; Emil Aaltonen 
Foundation; and Yrjö Jahnsson Foundation. 
AGES  The researchers are indebted to the participants for their 
willingness to participate in the study. This study was funded by 
NIH contracts N01-AG-1-2100 and 271201200022C, the NIA 
Intramural Research Program, Hjartavernd (the Icelandic Heart 
Association), and the Althingi (the Icelandic Parliament). The 
study was approved by the Icelandic National Bioethics 
Committee, VSN: 00-063.  
ARIC  The Atherosclerosis Risk in Communities Study was carried out 
as a collaborative study supported by National Heart, Lung, and 
Blood Institute contracts (HHSN268201100005C, 
HHSN268201100006C, HHSN268201100007C, 
HHSN268201100008C, HHSN268201100009C, 
HHSN268201100010C, HHSN268201100011C, and 
HHSN268201100012C), R01HL087641, R01HL59367 and 
R01HL086694; National Human Genome Research Institute 
contract U01HG004402; and National Institutes of Health contract 
HHSN268200625226C. 
CHS  Infrastructure for the CHARGE Consortium was supported in part 
by the National Heart, Lung, and Blood Institute grant 
R01HL105756. This CHS research was supported by NHLBI 
contracts HHSN268201200036C, HHSN268200800007C, 
N01HC55222, N01HC85079, N01HC85080, N01HC85081, 
N01HC85082, N01HC85083, N01HC85086; and NHLBI grants 
U01HL080295, R01HL087652, R01HL105756, R01HL103612, 
and R01HL120393 with additional contribution from the National 
Institute of Neurological Disorders and Stroke (NINDS). Additional 
support was provided through R01AG023629 from the National 
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Institute on Aging (NIA). A full list of principal CHS investigators 
and institutions can be found at CHS-NHLBI.org. The provision of 
genotyping data was supported in part by the National Center for 
Advancing Translational Sciences, CTSI grant UL1TR000124, 
and the National Institute of Diabetes and Digestive and Kidney 
Disease Diabetes Research Center (DRC) grant DK063491 to the 
Southern California Diabetes Endocrinology Research Center. 
The content is solely the responsibility of the authors and does 
not necessarily represent the official views of the National 
Institutes of Health. 
FHS  We thank Dr. Curtis Ellison at Boston University School of 
Medicine for defining phenotypes. The Framingham Heart Study 
was funded by National Institutes of Health contract N01-HC-
25195. The laboratory work for this investigation was funded by 
the Division of Intramural Research, National Heart, Lung, and 
Blood Institute, National Institutes of Health, Bethesda, MD. The 
analytical component of this project was funded by the Division of 
Intramural Research, National Heart, Lung, and Blood Institute, 
and the Center for Information Technology, National Institutes of 
Health, Bethesda, MD. 
HABC  Health Aging and Body Composition Study (Health ABC): This 
study was funded by the National Institutes of Aging.  This 
research was supported by NIA contracts N01AG62101, 
N01AG62103, and N01AG62106. The genome-wide association 
study was funded by NIA grant 1R01AG032098-01A1 to Wake 
Forest University Health Sciences and genotyping services were 
provided by the Center for Inherited Disease Research (CIDR). 
CIDR was funded through a federal contract from the National 
Institutes of Health to The Johns Hopkins University, contract 
number HHSN268200782096C. 
MESA  MESA and the MESA SHARE project were conducted and 
supported by the National Heart, Lung, and Blood Institute 
(NHLBI) in collaboration with MESA investigators. Support for 
MESA was provided by contracts N01-HC-95159, N01-HC-95160, 
N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, 
N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, 
N01-HC-95169, UL1-TR-001079, and UL1-TR-000040. Funding 
for SHARe genotyping was provided by NHLBI Contract N02-HL-
64278.  Genotyping was performed at Affymetrix (Santa Clara, 
California, USA) and the Broad Institute of Harvard and MIT 
(Boston, Massachusetts, USA) using the Affymetrix Genome-
Wide Human SNP Array 6.0. The provision of genotyping data 
was supported in part by the National Center for Advancing 
Translational Sciences, CTSI grant UL1TR000124, and the 
National Institute of Diabetes and Digestive and Kidney Disease 
Diabetes Research Center (DRC) grant DK063491 to the 
Southern California Diabetes Endocrinology Research Center. 
RS 1, 2 and 3 The authors are grateful to the study participants, the staff from 
the Rotterdam Study and the participating general practitioners 
and pharmacists. We thank Pascal Arp, Mila Jhamai, Marijn 
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Verkerk, Lizbeth Herrera and Marjolein Peters, MSc, and Carolina 
Medina-Gomez, MSc, for their help in creating the GWAS 
database, and Karol Estrada, PhD, Yurii Aulchenko, PhD, and 
Carolina Medina-Gomez, MSc, for the creation of imputed data. 
The Rotterdam Study was funded by Erasmus Medical Center 
and Erasmus University, Rotterdam, Netherlands Organization for 
the Health Research and Development (ZonMw), the Research 
Institute for Diseases in the Elderly (RIDE), the Ministry of 
Education, Culture and Science, the Ministry for Health, Welfare 
and Sports, the European Commission (DG XII), and the 
Municipality of Rotterdam. The generation and management of 
GWAS genotype data for the Rotterdam Study (RS I, RS II, RS 
III) was executed by the Human Genotyping Facility of the 
Genetic Laboratory of the Department of Internal Medicine, 
Erasmus MC, Rotterdam, The Netherlands. The GWAS datasets 
are supported by the Netherlands Organisation of Scientific 
Research NWO Investments (175.010.2005.011, 911-03-012), 
the Genetic Laboratory of the Department of Internal Medicine, 
Erasmus MC, the Research Institute for Diseases in the Elderly 
(014-93-015; RIDE2), the Netherlands Genomics Initiative 
(NGI)/Netherlands Organisation for Scientific Research (NWO) 
Netherlands Consortium for Healthy Aging (NCHA), project 050-
060-810 . 
WGHS  The WGHS was supported by HL043851 and HL080467 from the 
National Heart, Lung, and Blood Institute and CA047988 from the 
National Cancer Institute, with collaborative scientific support and 
funding for genotyping provided by Amgen. 
Airwave  We thank all participants in the Airwave Health Monitoring Study. 
We also thank Louisa Cavaliero who assisted in data collection 
and management as well as Peter McFarlane and the Glasgow 
CARE, Patricia Munroe at Queen Mary University of London, 
Joanna Sarnecka and Ania Zawodniak at Northwick Park for their 
contributions to the study. The study was funded by the Home 
Office (Grant number 780-TETRA) with additional support from 
the National Institute for Health Research (NIHR), Imperial 
College Healthcare NHS Trust (ICHNT) and Imperial College 
Biomedical Research Centre (BRC). P.E. was supported by the 
ICHNT and Imperial College BRC, the MRC-PHE Centre for 
Environment and Health, the NIHR Health Protection Research 
Unit on Health Impact of Environmental Hazards and is an NIHR 
Senior Investigator. 
ASPS  The authors thank the staff and the participants for their valuable 
contributions. We thank Birgit Reinhart for her long-term 
administrative commitment, Elfi Hofer for the technical assistance 
at creating the DNA bank, Ing. Johann Semmler and Anita Harb 
for DNA sequencing and DNA analyses by TaqMan assays and 
Irmgard Poelzl for supervising the quality management processes 
after ISO9001 at the biobanking and DNA analyses. The research 
was funded by the Austrian Science Fond (FWF) grant number 
P20545-P05 and P13180. The Medical University of Graz 
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B58C  We acknowledge use of phenotype and genotype data from the 
British 1958 Birth Cohort DNA collection, funded by the Medical 
Research Council grant G0000934 and the Wellcome Trust grant 
068545/Z/02. Genotyping for the B58C-WTCCC subset was 
funded by the Wellcome Trust grant 076113/B/04/Z. The B58C-
T1DGC genotyping utilized resources provided by the Type 1 
Diabetes Genetics Consortium, a collaborative clinical study 
sponsored by the National Institute of Diabetes and Digestive and 
Kidney Diseases (NIDDK), National Institute of Allergy and 
Infectious Diseases (NIAID), National Human Genome Research 
Institute (NHGRI), National Institute of Child Health and Human 
Development (NICHD), and Juvenile Diabetes Research 
Foundation International (JDRF) and supported by U01 
DK062418. B58C-T1DGC GWAS data were deposited by the 
Diabetes and Inflammation Laboratory, Cambridge Institute for 
Medical Research (CIMR), University of Cambridge, which was 
funded by Juvenile Diabetes Research Foundation International, 
the Wellcome Trust and the National Institute for Health Research 
Cambridge Biomedical Research Centre; the CIMR was in receipt 
of a Wellcome Trust Strategic Award (079895). The B58C-
GABRIEL genotyping was supported by a contract from the 
European Commission Framework Programme 6 (018996) and 
grants from the French Ministry of Research. 
DESIR  We thank the subjects and families who participated in this study. 
We thank F. Allegaert, M. Deweirder for their technical support in 
DNA extraction and distribution. This work was supported by 
grants from the ‘‘Agence Nationale de la Recherche,’’ the 
‘‘Conseil Regional Nord-Pas de Calais/Fonds europeen de 
dveloppement economique et r´egional,’’ Genome 
Quebec/Genome Canada and the Medical Research Council 
FTC_replication We warmly thank the participating twin pairs and their family 
members for their contribution. We express our appreciation to 
the skilled study interviewers A-M Iivonen, K Karhu, H-M Kuha, U 
Kulmala-Gråhn, M Mantere, K Saanakorpi, M Saarinen, R Sipilä, 
L Viljanen and E Voipio. Anja Häppölä and Kauko Heikkilä are 
acknowledged for their valuable contribution in recruitment, data 
collection, and data management. Antti-Pekka Sarin and Samuli 
Ripatti are acknowledged for genotype data quality controls and 
imputation. Phenotyping and genotyping of the Finnish twin 
cohorts was supported by the Academy of Finland Center of 
Excellence in Complex Disease Genetics (grants 213506, 
129680), the Academy of Finland (grants 100499, 205585, 
118555, 141054, 265240, 263278 and 264146 to J. Kaprio), 
National Institute of Alcohol Abuse and Alcoholism (grants AA-
12502, AA-00145, and AA-09203 to R. J. Rose and AA15416 and 
K02AA018755 to D. M. Dick), Sigrid Juselius Foundation (to J. 
Kaprio), Global Research Award for Nicotine Dependence, Pfizer 
Inc. (to J. Kaprio), the Welcome Trust Sanger Institute, UK, and 
the Broad Institute, USA. 
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GRAPHIC  We thank all the participants in the study for their contribution and 
support. The GRAPHIC Study was funded by the British Heart 
Foundation (BHF). CPN and NJS were both funded by the BHF 
and NJS is a NIHR Senior Investigator. 
GS:SFHS  We are grateful to all the families who took part, the general 
practitioners and the Scottish School of Primary Care for their 
help in recruiting them, and the whole Generation Scotland team, 
which includes interviewers, computer and laboratory technicians, 
clerical workers, research scientists, volunteers, managers, 
receptionists, healthcare assistants and nurses. Generation 
Scotland received core funding from the Chief Scientist Office of 
the Scottish Government Health Directorates CZD/16/6 and the 
Scottish Funding Council HR03006. Genotyping of the GS:SFHS 
samples was carried out by the Genetics Core Laboratory at the 
Wellcome Trust Clinical Research Facility, Edinburgh, Scotland 
and was funded by the UK’s Medical Research Council and the 
Wellcome Trust. Ethics approval for the study was given by the 
NHS Tayside committee on research ethics (reference 
05/S1401/89).financial support received for this work from the Dr. 
Mortimer and Theresa Sackler Foundation and the MRC “QTL in 
Health and Disease” core programme. 
INGI_CARL  We thank all the participants in the study for their contribution and 
support. The INGI-FVG study was funded through the Italian 
Ministry of Health  
INGI_FVG  We thank all the participants in the study for their 
contribution and support. The INGI-CARL study was funded 
through the Italian Ministry of Health. 
INGI_VB  We thank all the participants to the project, the San Raffaele 
Hospital MDs who contributed to clinical data collection, Prof. 
Clara Camaschella  who coordinated  the data collection, Corrado 
Masciullo and Massimiliano Cocca for help in the  database 
informatics. The research was supported by funds from 
Compagnia di San Paolo, Torino, Italy; Fondazione Cariplo, Italy; 
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2011-2012 and Public Health Genomics Project 2010. 
LBC1921  We thank the cohort participants and team members who 
contributed to these studies. Phenotype collection in the LBC1921 
was supported by the BBSRC, The Royal Society, and The Chief 
Scientist Office of the Scottish Government. Genotyping was 
funded by the BBSRC. The work was undertaken by The 
University of Edinburgh Centre for Cognitive Ageing and 
Cognitive Epidemiology, part of the cross council Lifelong Health 
and Wellbeing Initiative (MR/K026992/1). Funding from the 
BBSRC and MRC is gratefully acknowledged. 
LBC1936  We thank the cohort participants and team members who 
contributed to these studies. Phenotype collection in the LBC1936 
was supported by Age UK (The Disconnected Mind project). 
Genotyping of the cohorts was funded by the BBSRC. The work 
was undertaken by The University of Edinburgh Centre for 
Cognitive Ageing and Cognitive Epidemiology, part of the cross 
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Funding from the BBSRC and MRC is gratefully acknowledged. 
NSPHS  We are grateful for the contribution of district nurse Svea Hennix 
for data collection and Inger Jonasson for logistics and 
coordination of the health survey. We also thank all the 
participants from the community for their interest and willingness 
to contribute to this study. Illumina genotyping was performed by 
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computations were performed on resources provided by SNIC 
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Table S1. Sex-specific associations of SNPs taken forward for replication from discovery GWAS. 
 
                Men Women 
Alcohol 
phenotype 
SNP Gene Chr Position Effect 
allele 
Other 
allele 
EAF Effect* SE P-value Effect SE P-value 
log g/day rs780094 GCKR 2 27594741 T C 0.403 -0.015 0.004 4.0x10-4 -0.015 0.003 9.6x10-6 
log g/day rs197273 TANK 2 161602909 A G 0.487 -0.018 0.004 4.8x10-5 -0.010 0.003 2.1x10-3 
log g/day rs10950202 AUTS2 7 69568034 C G 0.842 0.020 0.006 5.7x10-4 0.018 0.005 5.1x10-4 
log g/day rs11940694 KLB 4 39091388 A G 0.422 -0.017 0.004 8.7x10-5 -0.011 0.003 9.8x10-4 
log g/day rs350721 ASB3 2 52833931 C G 0.175 0.024 0.007 4.0x10-4 0.021 0.005 2.8x10-5 
log g/day rs6943555 AUTS2 7 69806023 A T 0.289 -0.012 0.005 9.9x10-3 -0.012 0.004 3.3x10-3 
dichotomous rs12599112 CDH13 16 81276212 A C 0.957 0.053 0.091 0.560 -0.063 0.015 2.4x10-5 
dichotomous rs10927848 TMEM82 1 15948493 A G 0.321 0.027 0.036 0.450 -0.023 0.008 2.5x10-3 
* Effect refers to beta coefficient from linear regression for log g/day alcohol phenotype, and log(OR) from logistic regression for 
dichotomous alcohol phenotype. 
 
 
Table S2. Dichotomous trait replication results 
 
SNP Chr 
Position 
(hg19) 
Gene* 
Discovery 
P 
Replication 
P 
Overall 
P 
Overall 
N 
rs12599112 16 82718711 CDH13 2.3x10-8 0.895 5.0x10-8 86,213 
rs10927848 1 16075906 TMEM82 2.6x10-7 0.291 1.9x10-7 103,219 
Cohorts - Airwave, ASPS, B58C, FinnTwin_replication, GRAPHIC, GS:SFHS, 
INGI_CARL, INGI_FVG, INGI_VB, LBC1921, LBC1936, PROSPER 
The most significant SNP per locus is displayed in the tables. 
* Loci are named according to the closest gene based on the position of the most 
significant SNP.  
Table S3. Allele frequencies of the KLB SNP rs11940694 in different ethnic groups 
Ethnicity Sample 
(2N) 
Major Allele 
Frequency 
Minor Allele 
frequency 
Ad-mixture American 694 A=0.565 G=0.435 
African 1322 G=0.570 A=0.430 
East Asian 1008 A=0.541 G=0.459 
South Asian 978 A=0.630 G=0.370 
European 1006 G=0.612 A=0.388 
 
 
Table S4. Gene expression in peripheral blood in the Framingham Heart Study 
(A) Demographics for gene expression analysis in Framingham Heart study 
Phenotypes/Covariates 
Offspring Cohort 
 (examination cycle 8:  
2005-2008) 
Third Generation Cohort 
(examination cycle 2:  
2008-2011) 
Gene Expression Analysis n=2,222 n=3,014 
Female (%)    1,221 (54.95) 1,603 (53.10) 
Age (yrs), mean (SD) 66.41 (8.95) 46.88 (8.79) 
BMI (kg/m2), mean (SD) 28.04 (5.87) 28.31 (5.5.30) 
BMI: Body mass index 
 
 
(B) Association of KLB SNP rs11940694 with gene expression 
 chr  position 
Effect 
allele 
Beta P-value 
rs11940694 4 39414993 A 0.00409 0.165 
 
 
Supplementary Figure legends 
Figure S1. Forest plot for the association of rs11940694 in KLB with log g/day 
alcohol in the discovery GWAS and replication cohorts. (A) rs11940694 in KLB 
in discovery GWAS cohorts. Discovery GWAS cohorts - AlcGen: Colaus, EGCUT, 
EPIC-Norfolk, ERF, Fenland, FinnTwinOld_2, HBCS, KORA F3 and F4, Lifelines, 
LOLIPOP (EW A, EW P, EW610), FinnTwinOld_3, NESDA, NFBC1966, NTR, 
OZALC, SHIP, TwinsUK, YFS; CHARGE+: AGES, CHS, FHS, HABC, MESA, RS1, 
RS2, RS2, and WGHS. In rs11940694, the coded allele was A, the non-coded allele 
was G. The allele frequency for A was ~ 0.42 in the entire sample. The beta/SE 
estimates were for A allele.  (B) rs11940694 in KLB in discovery + replication cohorts. 
The coded allele was A, the non-coded allele was G. The beta/SE estimates were for 
A allele.      
Figure S2. Genome-wide association results of dichotomous alcohol in AlcGen 
and CHARGE+ consortia. (A) Manhattan plot showing the significance of the 
association (–log10 transformed P value on the y axis) for each SNP at chromosomal 
position shown on the x axis. The dotted line represents the genome-wide 
significance level at P = 5x10-8. The genes that were followed up are labelled. (B) 
Quantile-quantile plot comparing the expected P value on the x axis and the 
observed P value on the y axis (both were –log10 transformed). 
Figure S3. Illustration of common SNPs (minor allele frequency > 0.01) and 
linkage disequilibrium (LD) structure in the genomic regions around the KLB 
gene. The target SNP rs11940694 is highlighted with black background and pointed 
to by a red arrow in the LD structure plot. LD is measured by r-square and the darker 
the red color, the higher the r-square value. 
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